Topical Mastitis Composition Using Stem Cell Conditioned Medium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mastitis treatment methods, particularly in the dairy industry, face challenges such as high economic losses, antibiotic resistance, skin irritation from iodine-based products, and the inability to prevent future occurrences or address milk production decline, highlighting the need for effective, easy-to-use compositions that can treat and prevent mastitis while reducing inflammation and irritation.
Innovation Solution
A composition containing conditioned medium from a unique line of mesenchymal stem cells derived from Wistar rat bone marrow, characterized by specific markers and growth factor production, which is used topically or orally to reduce somatic cell count and incidence of mastitis, and includes antimicrobial and film-forming agents to create a protective barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat mastitis, then clinical symptoms are effectively treated, but milk must be discarded for several days and antibiotic resistance develops
Solution Approach 1:
The patent uses iodine as an intermediary antiseptic agent applied topically to the teat and udder area. This mediator provides antimicrobial action without requiring systemic antibiotic administration, thereby eliminating the need to discard milk while still effectively treating mastitis. The iodine-based composition acts as a local intermediary treatment that prevents bacterial invasion and colonization.
Solution Approach 2:
The invention extracts the treatment action from systemic antibiotic administration and relocates it to topical application. By removing antibiotics from the systemic circulation and applying them locally to the affected area (teat and udder), the treatment maintains effectiveness while avoiding the side effect of milk contamination and subsequent discard.
2Reliability
If iodine-based products are used for mastitis treatment, then antimicrobial effect is achieved, but skin irritation occurs
Solution Approach 1:
The patent combines iodine with other compatible ingredients to create a composite topical composition. This composite formulation includes iodine as the active antimicrobial agent along with additional components that enhance skin compatibility and reduce irritation. The composite material approach allows the beneficial antimicrobial properties of iodine to be retained while mitigating its harmful irritating effects through synergistic combination with other substances.
3Reliability
If conventional treatments are used, then current symptoms are addressed, but future mastitis occurrences are not prevented
Solution Approach 1:
The patent applies iodine-based compositions prophylactically to the teat and udder area before bacterial invasion occurs. This preliminary action creates a protective barrier that prevents mastitis development in the first place, rather than merely treating symptoms after infection has established. The topical application anticipates potential bacterial contact and neutralizes the threat before it can cause clinical mastitis.
Solution Approach 2:
The invention establishes continuous protective action through repeated topical applications of the iodine-based composition. Rather than a single curative treatment, the regimen involves ongoing application to maintain antimicrobial protection, ensuring both treatment of current issues and prevention of future occurrences. This continuous useful action bridges the gap between symptomatic relief and long-term prevention.
Data Source
AI summary
Aspects of the invention relate to a novel mesenchymal stem cell line (hb-MSC), a culture medium conditioned by the hb-MSC line, and various hb-MSC compositions. The hb-MSC compositions may include a plurality of hb-MSCs, the hb-MSC conditioned medium, or a combination thereof. The hb-MSC compositions may also include one or more of an antimicrobial agent, a film-forming agent, an appropriate carrier, as well as other additives as determined by the application. Also described are methods of use for the hb-MSC cells, the conditioned medium, and the compositions, including methods of treating or preventing bovine mastitis.